Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
m (→Also known as) |
Warner-admin (talk | contribs) m |
||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Acute myeloid leukemia]] | + | *[[Acute myeloid leukemia, IDH-mutated]] |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *8/1/2017: Granted [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm FDA regular approval] "for the treatment of adult patients with relapsed or refractory [[ | + | *8/1/2017: Granted [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm FDA regular approval] "for the treatment of adult patients with relapsed or refractory [[Acute myeloid leukemia, IDH-mutated|acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation]] as detected by an FDA-approved test. |
==Also known as== | ==Also known as== | ||
| Line 14: | Line 14: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
Revision as of 02:02, 23 January 2018
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).
Diseases for which it is used
History of changes in FDA indication
- 8/1/2017: Granted FDA regular approval "for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Also known as
- Code names: AG-221, CC-90007
- Brand name: Idhifa